Login to Your Account



Ardea Licenses MEK Inhibitors to Bayer in Deal Valued at $407M

By Catherine Hollingsworth


Wednesday, April 29, 2009
Ardea Biosciences Inc. licensed its MEK inhibitors to Bayer Healthcare AG to develop potential treatments for cancer, in a deal worth up to $407 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription